Related Experiment Video

Updated: Aug 12, 2026

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Prostaglandin E inhibition of mitogen stimulation in patients with multiple sclerosis

J S Goodwin, R P Messner

    Prostaglandins
    |February 1, 1978
    PubMed

    Insights

    Prostaglandin E2 (PGE2) does not suppress immune cell function in multiple sclerosis (MS) patients, contrary to previous findings. This study found no difference in PGE2 sensitivity or suppressor cell activity between MS patients and healthy individuals.

    Area of Science:

    • Immunology
    • Neuroimmunology
    • Prostaglandin research

    Background:

    • Leukocyte function in multiple sclerosis (MS) patients may differ from normal individuals.
    • Previous research suggested Prostaglandin E2 (PGE2) suppresses normal leukocyte function.

    Purpose of the Study:

    • To investigate the effect of PGE2 on lymphocyte proliferation in MS patients.
    • To compare PGE2 sensitivity in lymphocytes from MS patients and healthy controls.
    • To assess the activity of prostaglandin-producing suppressor cells in MS.

    Main Methods:

    • Peripheral blood lymphocytes were isolated from MS patients and normal controls.
    • Phytohemagglutinin-induced 3H-thymidine incorporation was measured.
    • The ability of PGE2 (0.01-0.5 microgram/ml) to suppress lymphocyte proliferation was assessed.
    • Prostaglandin-producing suppressor cell activity was evaluated.

    Main Results:

    • PGE2 did not suppress lymphocyte proliferation in MS patients.
    • There was no significant difference in PGE2 sensitivity between MS patients and controls.
    • No difference in the activity of prostaglandin-producing suppressor cells was observed between the groups.

    Conclusions:

    • The findings contradict previous reports suggesting impaired PGE2-mediated suppression in MS.
    • Lymphocyte response to PGE2 is similar in multiple sclerosis patients and healthy individuals.
    • Prostaglandin-producing suppressor cell activity is not altered in MS patients.

    More Related Videos

    Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE09:24

    Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

    Published on: April 15, 2014

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

    Published on: October 13, 2023

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...